Atezolizumab increased OS by 7.1 months compared with chemotherapy (median OS 20.2 versus 13.1 months; HR 0.59, 95% CI 0.40–0.89; p = 0.0106) in patients with elevated PD-L1 expression (tumor cell (TC)3 o tumor-infiltrating immune cell (IC)3-wild-type). This evidence concerns the gene CD274 and neoplasm.